Checking and treating blood sugar in pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a plan to monitor and manage blood sugar in people with pancreatic ductal cancer who are starting a specific chemotherapy regimen (FOLFIRINOX). The goal is to prevent or address high blood sugar during treatment, which may help people stay on therapy safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have pancreatic ductal adenocarcinoma (PDAC) confirmed by lab tests (biopsy/cytology).
- Your first treatment plan for advanced pancreatic cancer includes FOLFIRINOX chemotherapy (given as planned first-line systemic therapy).
- You are 18 or older and can do daily activities with little or no limitation (ECOG 0–1).
- Your blood counts and organ tests must be within safe ranges (white blood cells, platelets, hemoglobin, kidney function, liver tests, and potassium).
- Your cancer must be measurable on scans and must be life expectancy greater than 90 days, according to the study doctor.
- You can take pills and the study team must feel you can safely receive insulin under the skin if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding focused ultrasound (IMD10) to standard chemotherapy helps treat pancreatic cancer that is borderline or locally advanced and cannot be removed by surgery right away. It may shrink the tumor enough to allow surgery later.
This trial is for people who had surgery for pancreatic cancer and are now deciding on maintenance therapy. A special blood test (ctDNA) may help doctors choose the best follow-up treatment to prevent the cancer from coming back.
This trial tests adding sitagliptin (a diabetes drug) to standard chemotherapy (gemcitabine and nab-paclitaxel) for people with pancreatic cancer that has spread or cannot be removed by surgery. The goal is to see if the combination works better than chemo alone.
This trial uses a special gene test on fluid taken from an endoscopic ultrasound (EUS) biopsy to help choose chemotherapy before surgery for pancreas cancer. It aims to see if this approach improves outcomes by matching treatment to the tumor’s RNA pattern.
This study tests whether adding a diabetes treatment to standard chemotherapy helps people with pancreatic cancer that has spread and who also have diabetes. It might improve how well the cancer is controlled and how you feel.
This study uses small pancreatic cancer samples grown in the lab to understand which treatments may work best for people with pancreatic cancer. It may help researchers better “profile” tumors so standard care can be matched to the most effective options.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.